168 related articles for article (PubMed ID: 35311871)
1. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC).
Chotitumnavee J; Yamashita Y; Takahashi Y; Takada Y; Iida T; Oba M; Itoh Y; Suzuki T
Chem Commun (Camb); 2022 Apr; 58(29):4635-4638. PubMed ID: 35311871
[TBL] [Abstract][Full Text] [Related]
2. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity.
Zhao C; Chen D; Suo F; Setroikromo R; Quax WJ; Dekker FJ
Bioorg Chem; 2023 Jul; 136():106546. PubMed ID: 37098288
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
[TBL] [Abstract][Full Text] [Related]
4. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
[TBL] [Abstract][Full Text] [Related]
5. PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.
Smalley JP; Adams GE; Millard CJ; Song Y; Norris JKS; Schwabe JWR; Cowley SM; Hodgkinson JT
Chem Commun (Camb); 2020 Apr; 56(32):4476-4479. PubMed ID: 32201871
[TBL] [Abstract][Full Text] [Related]
6. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
7. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Cao F; de Weerd S; Chen D; Zwinderman MRH; van der Wouden PE; Dekker FJ
Eur J Med Chem; 2020 Dec; 208():112800. PubMed ID: 32971411
[TBL] [Abstract][Full Text] [Related]
8. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity.
Huang J; Zhang J; Xu W; Wu Q; Zeng R; Liu Z; Tao W; Chen Q; Wang Y; Zhu WG
J Med Chem; 2023 Jan; 66(2):1186-1209. PubMed ID: 36516047
[TBL] [Abstract][Full Text] [Related]
11. Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.
Kleinschek A; Meyners C; Digiorgio E; Brancolini C; Meyer-Almes FJ
ChemMedChem; 2016 Dec; 11(23):2598-2606. PubMed ID: 27860422
[TBL] [Abstract][Full Text] [Related]
12. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
[TBL] [Abstract][Full Text] [Related]
13. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
14. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
15. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Amin SA; Khatun S; Gayen S; Das S; Jha T
Eur J Med Chem; 2023 Oct; 258():115594. PubMed ID: 37429084
[TBL] [Abstract][Full Text] [Related]
16. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry.
Rajaraman S; Balakrishnan R; Deshmukh D; Ganorkar A; Biswas S; Pulya S; Ghosh B
Future Med Chem; 2023 May; 15(10):885-908. PubMed ID: 37227732
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Design and Development of PROTAC-mediated HDAC Degradation.
Rodrigues DA; Roe A; Griffith D; Chonghaile TN
Curr Top Med Chem; 2022 Mar; 22(5):408-424. PubMed ID: 34649488
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
20. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
